Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01448850 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 464
- Enrollment target
NCT01448850: Completed Phase 2 study, sponsored by MedImmune.
NCT01448850 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 464 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (249% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01448850, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 464 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease - GOLD stage II-IV) receiving standard maintenance therapy for the underlying disease condition.
Primary Outcome
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days. The severity of an AECOPD is defined as: Moderate exacerbations require treatment with systemic corticosteroids, and or antibiotics. Severe exacerbations require hospitalization. The AECOPD rate was analyzed using a Poisson Regression model adjusted for over dispersion with number of exacerbations as the outcome and the log of follow-up time as an offset variable,
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI8968 600 mg IV, 300 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01448850 record still lists
NCT01448850 is an interventional study that assigns participants to a tested intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (249% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01448850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01448850 about?
NCT01448850 is a clinical study titled "A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease". The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease - GOLD stag...
What is the current status of trial NCT01448850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 464 participants. The study started on 2011-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01448850?
The interventions under investigation include: Placebo (OTHER), MEDI8968 600 mg IV, 300 mg SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT01448850?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01448850's enrollment target sits among peer trials
464 81st of 2000 higher than 1,919 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia